Atazanavir - A once-daily HIV protease inhibitor that does not cause dyslipidemia in newly treated patients: Results from two randomized clinical trials

Journal of the International Association of Physicians in AIDS Care

Volumn 3, Issue 3, 2004, Pages 92-98

  Cahn, Pedro E ^a   Gatell, José M ^b   Squires, Kathleen ^c   Percival, Lisa D ^d   Piliero, Peter J ^e   Sanne, Ian A ^f   Shelton, Sarah ^d   Lazzarin, Adriano ^g   Odeshoo, Linda ^c   Kelleher, Thomas D ^c   Thiry, Alexandra ^d   Giordano, Michael D ^d   Schnittman, Stephen M ^d  

^a FUNDACIÓN HUÉSPED   (Argentina)

^b HOSPITAL CLÍNIC   (Spain)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d BRISTOL MYERS SQUIBB   (United States)

^e ALBANY MEDICAL COLLEGE   (United States)

^f WHC Infect Dis Clin Trials Unit   (South Africa)

^g SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

atazanavir; HIV protease inhibitors; hypercholesterolemia; hyperlipidemia; hypertriglyceridemia; nelfinavir

Indexed keywords

ATAZANAVIR; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OLIGOPEPTIDE; PROTEINASE INHIBITOR; PYRIDINE DERIVATIVE; TRIACYLGLYCEROL;

BLOOD; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG ADMINISTRATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; METHODOLOGY; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; REVIEW;

ADMINISTRATION, ORAL; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DRUG ADMINISTRATION SCHEDULE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; HYPERLIPIDEMIAS; LIPIDS; OLIGOPEPTIDES; PYRIDINES; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN; TRIGLYCERIDES;

EID: 13644260227     PISSN: 15451097     EISSN: 15570886     Source Type: Journal    
DOI: 10.1177/154510970400300304     Document Type: Article

References (46)

1. Tsiodras S, Mantzoros C, Hammer S, Samore M. Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: A 5-year cohort study. Arch Intern Med 2000 ; 160: 2050-2056. (Pubitemid 30437589)
2. Chang ES, Tetreault DD, Liu YT, Beall GN. The effects of antiretroviral protease inhibitors on serum lipid levels in HIV-infected patients. J Am Diet Assoc 2001 ; 101: 687-689. (Pubitemid 33714119)
3. Dubé MP, Qian D, Edmondson-Melançon H, et al. Prospective, intensive study of metabolic changes associated with 48 weeks of amprenavir-based antiretroviral therapy. Clin Infect Dis 2002 ; 35: 475-481. (Pubitemid 34852578)
4. Stein JH. Dyslipidemia in the era of HIV protease inhibitors. Prog Cardiovasc Dis 2003 ; 45: 293-304. (Pubitemid 36293025)
5. Fontas E, van Leth F, Sabin CA, et al. Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: Are different antiretroviral drugs associated with different lipid profiles? J Infect Dis 2004 ; 189: 1056-1074. (Pubitemid 38373099)
6. Green ML. Evaluation and management of dyslipidemia in patients with HIV infection. J Gen Intern Med 2002 ; 17: 797-810. (Pubitemid 35286246)
7. Staszewski S, Gallant JE, Pozniak AL, et al. Favorable metabolic profile for tenofovir disoproxil fumarate (TDF) versus stavudine (d4T) when used in combination with lamivudine and efavirenz in antiretroviral naive patients: 96-week interim results. 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment. July 13-16, 2003. Paris, France. (Abstract 562).
8. Kumar P, Rodriguez-French A, Thompson M, et al. Prospective study of hyperlipidemia in ART-naive subjects taking combivir/abacavir (COM/ABC), COM/nelfinavir (NFV), or stavudine (d4T)/lamivudine (3TC)/NFV (ESS40002). 9th Conference on Retroviruses and Opportunistic Infections. February 24-28, 2002. Seattle, WA, USA. (Abstract 33). Accessed March 8, 2004 from http://www.retroconference.org/2002/Abstract/13081.htm
9. van der Valk M, Kastelein JJ, Murphy RL, et al. Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile. AIDS 2001 ; 15: 2407-2414. (Pubitemid 34014609)
10. van Leth F, Phanuphak P, Gazzard B, et al. Lipid changes in a randomized comparative trial of first-line antiretroviral therapy with regimens containing either nevirapine alone, efavirenz alone or both drugs combined, together with stavudine and lamivudine (2NN Study). 10th Conference on Retroviruses and Opportunistic Infections. February 10-14, 2003. Boston, MA, USA. (Poster 752). Accessed March 8, 2004 from http://www.retroconference.org/2003/Abstract/ Abstract.aspx?AbstractID=97
11. Juette A, Salzberger B, Franzen C, Roemer K, Diehl V, Faetkenheuer G. Increased morbidity from severe coronary heart disease in HIV-patients receiving protease inhibitors. 6th Conference of Retroviruses and Opportunistic Infections. January 31-February 4, 1999. Chicago, IL, USA. (Abstract 656). Accessed August 12, 2003 from http://www.retroconference.org/99/abstracts/656. htm
12. Flynn TE, Bricker LA. Myocardial infarction in HIV-infected men receiving protease inhibitors. Ann Intern Med 1999 ; 131: 548. (Pubitemid 29482406)
13. Krishnaswamy G, Chi DS, Kelley JL, Sarubbi F, Smith JK, Peiris A. The cardiovascular and metabolic complications of HIV infection. Cardiol Rev 2000 ; 8: 260-268.
14. Rhew D, Kim M, Bernal M, Aguilar D, Iloeje U, Goetz MB. Association between protease inhibitors and increased cardiovascular risk: A systematic review. Antivir Ther 2002 ; 7: L38. (Abstract 56).
15. Holmberg SD, Moorman AC, Williamson JM, et al. Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet 2002 ; 360: 1747-1748. (Pubitemid 35447907)
16. Iloeje U, Yuan Y, Tuomari A, et al. Protease inhibitors may increase risk of cardiovascular disease in HIV-infected patients. 10th Conference on Retroviruses and Opportunistic Infections. February 10-14, 2003. Boston, MA, USA. (Poster 746). Accessed: May 6, 2004 from http://www.retroconference.org/ 2003/Abstract/Abstract.aspx?AbstractID=630
17. Mary-Krause M, Cotte L, Simon A, et al. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS 2003 ; 17: 2479-2486. (Pubitemid 38393320)
18. Bozzette SA, Ake CF, Tam HK, Chang SW, Louis TA. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 2003 ; 348: 702-710. (Pubitemid 36237039)
19. Stein JH, Klein MA, Bellehumeur JL, et al. Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation 2001 ; 104: 257-262. (Pubitemid 32666944)
20. Henry K, Melroe H, Huebsch J, et al. Severe premature coronary artery disease with protease inhibitors. Lancet 1998 ; 351: 1328. (Pubitemid 28195913)
21. Karmochkine M, Raguin G. Severe coronary artery disease in a young HIV-infected man with no cardiovascular risk factor who was treated with indinavir. AIDS 1998 ; 12: 2499. (Pubitemid 28558610)
22. Hsue PY, Lo JC, Franklin A, et al. Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection. Circulation 2004 ; 109: 1603-1608. (Pubitemid 38451715)
23. Sanne I, Piliero P, Squires K, Thiry A, Schnittman S. Results of a phase 2 clinical trial at 48 weeks (AI424-007): A dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects. J Acquir Immune Defic Syndr 2003 ; 32: 18-29. (Pubitemid 36091481)
24. Murphy RL, Sanne I, Cahn P, et al. Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results. AIDS 2003 ; 17: 2603-2614. (Pubitemid 38402338)
25. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001 ; 285: 2486-2497.
26. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. (Adult Treatment Panel III). Final Report. National Heart, Lung and Blood Institute. National Institutes of Health. NIH Publication No. 02-5215. September 2002.
27. Moyle GJ, Gazzard BG. Switching to zidovudine plus lamivudine plus abacavir maintains viral suppression in patients with high viral load before antiretroviral therapy: A retrospective clinical cohort analysis. AIDS 2002 ; 16: 1086-1087. (Pubitemid 34499439)
28. Dubé MP, Sprecher D, Henry WK, et al. Preliminary guidelines for the evaluation and management of dyslipidemia in adults infected with human immunodeficiency virus and receiving antiretroviral therapy: Recommendations of the Adult AIDS Clinical Trial Group Cardiovascular Disease Focus Group. Clin Infect Dis 2000 ; 31: 1216-1224. (Pubitemid 32295453)
29. Dubé MP, Stein JH, Aberg JA, et al. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: Recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis 2003 ; 37: 613-627. (Pubitemid 37100800)
30. Schambelan M, Benson CA, Carr A, et al. Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: Recommendations of an International AIDS Society-USA panel. J Acquir Immune Defic Syndr 2002 ; 31: 257-275. (Pubitemid 35278626)
31. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994 ; 344: 1383-1389.
32. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995 ; 333: 1301-1307.
33. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996 ; 335: 1001-1009. (Pubitemid 26338729)
34. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998 ; 279: 1615-1622. (Pubitemid 28248586)
35. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998 ; 339: 1349-1357.
36. Iloeje UH, Yu-Isenberg KS, Ventura EP, Tuomari AV. Treatment of HIV-associated dyslipidemia: A time trend analysis 1998-2001. Antivir Ther 2002 ; 7: L29. (Abstract 42).
37. Wood R, Phanuphak P, Cahn P, et al. Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or atazanavir. J Acquir Immune Defic Syndr 2004 ; 36: 684-692. (Pubitemid 38685962)
38. Périard D, Telenti A, Sudre P, et al. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. Circulation 1999 ; 100: 700-705. (Pubitemid 29383638)
39. Penzak SR, Chuck SK. Hyperlipidemia associated with HIV protease inhibitor use: Pathophysiology, prevalence, risk factors and treatment. Scand J Infect Dis 2000 ; 32: 111-123. (Pubitemid 30599192)
40. Cooper CL, van Heeswijk RP, Gallicano K, Cameron DW. A review of low-dose ritonavir in protease inhibitor combination therapy. Clin Infect Dis 2003 ; 36: 1585-1592. (Pubitemid 36783344)
41. Calza L, Manfredi R, Farneti B, Chiodo F. Incidence of hyperlipidaemia in a cohort of 212 HIV-infected patients receiving a protease inhibitor-based antiretroviral therapy. Int J Antimicrob Agents 2003 ; 22: 54-59. (Pubitemid 36808718)
42. Horban A, Staszewski S, Walmsley S, Pierone G, Sexton A, Stark T. Favourable increases in high-density lipoprotein cholesterol (HDL-C) concentrations in chronic HIV-infected therapy naive subjects receiving 908/R QD in the SOLO study. 9th European AIDS Conference (EACS). 1st EACS Resistance & Pharmacology Workshop. October 25-29, 2003. Warsaw, Poland. (Abstract F8/3). Accessed June 16, 2004 from http://www.aegis.com/conferences/eacs2003/41. html
43. Schürmann D, Gathe J, Sanne I, Wood R. Efficacy and safety of GW433908/ritonavir once daily in therapy-naive subjects, 48 week results: The SOLO Study. 6th International Congress on Drug Therapy in HIV Infection. November 17-21, 202. Glasgow, UK. (Abstract PL14.4).
44. Gathe J, Podzamczer D, Johnson M, et al. Once-daily vs. twice-daily lopinavir/ritonavir in antiretroviral-naive patients: 48-week results. 11th Conference on Retroviruses and Opportunistic Infections. February 8-11, 2004. San Francisco, CA, USA. (Abstract 570). Accessed June 17, 2004 from http://www.retroconference.org/2004/cd/Abstract/570.htm
45. Haas DW, Zala C, Schrader S, et al. Therapy with atazanavir plus saquinavir in patients failing highly active antiretroviral therapy: A randomized comparative pilot trial. AIDS 2003 ; 17: 1339-1349. (Pubitemid 36819848)
46. Clotet B, Lazzarin A, Grinsztejn B, Lichtenstein K, Sankoh S, Wilber R. Safety assessment of patients receiving atazanavir (ATV) with ritonavir (RTV), ATV with saquinavir (SQV), or lopinavir (LPV)/RTV: 48-week results from BMS A1424-045. 13th International Symposium on HIV & Emerging Infectious Diseases. June 3-5, 2004. Toulon, France. (Abstract PP 4.57). Accessed June 14, 2004 from http://www.isheid.com/faq-286.htm